Literature DB >> 28638311

A Variant in RUNX3 Is Associated with the Risk of Ankylosing Spondylitis in Koreans.

Sung-Min Cho1,2,3, Seung-Hyun Jung3,4, Yeun-Jun Chung1,2,3.   

Abstract

Ankylosing spondylitis (AS) is a chronic autoinflammatory disease that affects the spine and sacroiliac joints. Regarding its etiology, although HLA-B27 is known to be the strongest genetic factor of AS, much evidence suggests the potential contribution of non-MHC genes to the susceptibility to AS. Most of these non-MHC genes have been discovered in non-Asian populations; however, just some of them have been validated in Koreans. In this study, we aimed to identify additional AS-associated single-nucleotide polymorphism (SNP) candidates by replicating the candidate SNPs in Korean AS patients and healthy controls. For this, we selected three SNPs (rs11249215 in RUNX3, rs6556416 in IL12B, and rs8070463 in TBKBP1), which were previously reported as risk factors of AS but have not been studied in Koreans, and performed genotyping assays using a total of 1138 Korean samples (572 AS patients and 566 healthy controls). Of the three SNP candidates, one SNP in RUNX3 (rs11249215) was significantly associated with the risk of AS (odds ratio, 1.31; 95% confidence interval, 1.02 to 1.68, p = 0.03). These results will be helpful in elucidating the pathogenesis of AS and may be useful for developing AS risk prediction models in Koreans.

Entities:  

Keywords:  HLA-B27; ankylosing spondylitis; single nucleotide polymorphism

Year:  2017        PMID: 28638311      PMCID: PMC5478709          DOI: 10.5808/GI.2017.15.2.65

Source DB:  PubMed          Journal:  Genomics Inform        ISSN: 1598-866X


Introduction

Ankylosing spondylitis (AS) is a type of chronic autoinflammatory disease that affects the spine and sacroiliac joints. The pathogenesis of AS is not clear; however, it is believed to involve a combination of genetic and environmental factors. Among them, human leukocyte antigen B27 (HLA-B27) is the strongest genetic factor of AS. More than 80% to 90% of patients with AS express HLA-B27, and the association between HLA-B27 and AS has been identified in many ethnic groups [1]. However, only a small portion of HLA-B27–positive individuals (<5%) develop AS, suggesting a potential contribution of non-MHC genes to the susceptibility to AS [2]. A number of genome-wide association studies (GWASs) of single-nucleotide polymorphisms (SNPs) have identified non-MHC genes associated with AS, such as IL-12B, ERAP1, RUNX3, IL1R2, and ANTXR2 [3456]. In addition to SNPs, through genomewide copy number variant (CNV) analysis, CNVs associated with AS have also been identified [7]. These AS-associated non-MHC genes support the contribution of non-MHC genes to the susceptibility to AS. They can also be valuable markers of the development of AS. From a clinical point of view, the identification of early AS before the appearance of radiological changes in the patient's spine or sacroiliac joint is important, because current treatment options, such as tumor necrosis factor-α (TNF-α) inhibitors and nonsteroidal anti-inflammatory drugs, after these changes have occurred cannot block or slow down disease progression [8]. Instead, many reports suggest that earlier treatment of TNF-α inhibitors may prevent the progression of AS more effectively [8910]. In our previous work, to identify AS-associated SNP candidates in Koreans, we selected seven AS-associated SNP candidates, which had been identified in Caucasians by a GWAS and consistently replicated in East Asians, and performed a replication study with 285 Korean AS cases and 363 healthy controls [11]. However, in contrast to our expectation, only one of them was replicated in Koreans. In this study, to identify other AS-associated SNP candidates, we selected three SNPs in non-MHC genes from previous GWASs [451213] that are associated with AS but have not been tested in Koreans—rs11249215 in RUNX3, rs6556416 in IL12B, and rs8070463 in TBKBP1—and examined them in a large cohort of Koreans with AS and healthy controls.

Methods

Study subjects

A total of 1,138 individuals (572 AS patients and 566 healthy controls) were enrolled in this study. All of them were from our previous CNV discovery study [1113]. All AS cases were diagnosed according to the Modified New York Criteria [14]. This study was performed with the approval of the Institutional Review Board of the College of Medicine, Catholic University of Korea (CUMC10U170). The patients were aged 26.7 ± 11.8 years (85.3% male and 14.7% female), and 97.9% of them were HLA-B27–positive. The controls were aged 23.9 ± 11.8 years (94.7% male and 5.3% female), and 2.6% of them were HLA-B27–positive.

SNP genotyping

In this study, we selected three SNPs in non-MHC genes from previous GWASs [4, 5, 1213] that are associated with AS but have not been tested in Koreans: rs11249215 in RUNX3, rs6556416 in IL12B, and rs8070463 in TBKBP1. SNP genotyping was performed using the ViiA7 system (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The thermal cycling program included one cycle at 95℃ for 10 min, followed by 40 cycles at 95℃ for 15 s and 60℃ for 1 min, and a final extension at 60℃ for 30 s. Genotypes were determined using ViiA7 software, version 1.2 (Life Technologies).

Statistical analysis

The differences in allele and genotype frequencies between cases and controls were assessed using chi-squared test and Fisher exact test. Three genetic models (dominant, recessive, and allele) were used to test the SNP associations. Hardy-Weinberg equilibrium had been tested for all three SNPs, and their genotypes were in Hardy-Weinberg equilibrium in our cohort. Statistical analyses were performed using PLINK [15], and p-values less than 0.05 were considered to be significant in all statistical analyses.

Results

To evaluate the candidate AS-associated genetic markers, we selected three SNPs for a replication study in Koreans (rs11249215, rs6556416, and rs8070463) that have been previously reported as risk factors of AS but have not been studied in Koreans. All of them were located in non-exonic regions: rs11249215 was located in the promoter of RUNX3, rs6556416 was located in the 5'-flanking region of IL-12B, and rs8070463 was located in the promoter of TBKBP1. General information on the three SNPs is summarized in Table 1.
Table 1

General information for the three SNPs

SNP, single-nucleotide polymorphism; Genotype, reference allele/altered allele; MAF, minor allele frequencies; All, average of entire population; AFR, African; AMR, American; EAS, East Asian; EUR, European; SAS, South Asian.

aUCSC GRCh37/hg19.

We performed genotyping assays for the three SNPs using a total of 1,138 Koreans (572 AS patients and 566 healthy controls). Minor allele frequencies (MAFs) of the three SNPs in this study (0.57 for rs11249215, 0.91 for rs6556416, and 0.44 for rs8070463) were largely similar to those in East Asians from the 1000 Genomes Project, suggesting that our genotyping assays were reliable (Table 1). In the association analysis, one SNP in RUNX3 (rs11249215) was significantly associated with the risk of AS in the recessive model (Table 2). The MAF of rs11249215 was significantly higher in AS patients (MAF = 0.59) than in controls (MAF = 0.56) (odds ratio, 1.31; 95% confidence interval, 1.02 to 1.68; p = 0.03). However, significance was not detected in the allelic or dominant model for rs11249215. The other two SNPs in IL-12B and TBKBP1 showed increased odds ratios, but they were not statistically significant (Table 2).
Table 2

Association results for the three SNPs

SNP, single-nucleotide polymorphism; AF, allele frequency; HoF, homozygous risk allele frequencies; OR, odds ratio; CI, confidence interval.

Discussion

HLA-B27 is the strongest and most well-known genetic factor of AS. However, AS develops in less than 5% of HLA-B27–positive individuals, suggesting the existence of additional genetic factors. Indeed, a number of genetic markers in non-MHC genes have been identified by SNP GWASs and CNV GWASs [34567]. In this study, we performed an SNP genotyping assay to evaluate three AS-associated SNP candidates (rs11249215 in RUNX3, rs6556416 in IL12B, and rs8070463 in TBKBP1) that were discovered in Caucasians but have not been studied in Koreans. To generate more reliable data, we used a large sample set in this study (572 AS patients and 566 healthy controls). To our knowledge, this is the first report of the association of these three SNPs in Koreans. As a result, rs11249215 in RUNX3 was found to be significantly associated with the risk of AS in Koreans. However, rs6556416 in IL12B and rs4389526 in ANTXR2 were not replicated in Koreans. RUNX3 (Runt-related transcription factor 3) is a member of a family of transcription factors that are important regulators of lineage-specific gene expression. Woolf et al. [16] demonstrated that Runx3 is highly expressed in thymic medulla and that it promotes the differentiation of T cell to CD8+ T cells during thymopoiesis. More recently, RUNX3 was found to be linked to human autoimmune disease and inflammation. For example, Fainaru et al. [17] reported that Runx3 knockout mice develop spontaneous eosinophilic lung inflammation, which is attributed to dendritic cells becoming insensitive to transforming growth factor β–induced inhibition of maturation. RUNX3 polymorphisms are associated with the susceptibility to autoimmune diseases, such as systemic lupus erythematosus and psoriatic arthritis [1819]. Apel et al. [18] identified that RUNX3 is involved in CD8+ T lymphocyte differentiation and is related to psoriatic arthritis through a T cell–mediated mechanism. The association between the RUNX3 polymorphism rs11249215 and AS has also been reported in Caucasian [4] and Han Chinese populations [12]. Furthermore, Vecellio et al. [20] demonstrated that rs4648889 in RUNX3 is associated with AS and that its risk allele reduces RUNX3 expression. Consistent with previous studies, in this study, we confirmed that rs11249215 in RUNX3 is significantly associated with the risk of AS in Koreans in the recessive model. Because the homozygous risk allele frequency is important when an SNP is a recessive marker, we examined the homozygous risk allele frequency for rs11249215 and found that it was significantly higher in AS patients (homozygous risk allele frequencies [HoF] = 0.36) than in controls (HoF = 0.33) (Table 2). Of note, the MAF of rs11249215 in controls was largely similar to that in East Asians from the 1000 Genomes Project, suggesting that our study group was not biased and that the genotyping was appropriate. Because rs11249215 is located in the promoter of RUNX3, further studies on its molecular effects will help elucidate the pathogenesis of AS. In addition, considering that new SNPs are being reported to be associated with AS, other replication studies of newly identified SNPs are also needed. In conclusion, we performed a replication study of three SNPs with a relatively large cohort of samples and found that rs11249215 in RUNX3 is significantly associated with the risk of AS in Koreans. These results will be helpful in elucidating the pathogenesis of AS and may be useful for developing risk prediction models for AS in Koreans.
  20 in total

1.  A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis.

Authors:  Zhiming Lin; Jin-Xin Bei; Meixin Shen; Qiuxia Li; Zetao Liao; Yanli Zhang; Qing Lv; Qiujing Wei; Hui-Qi Low; Yun-Miao Guo; Shuangyan Cao; Mingcan Yang; Zaiying Hu; Manlong Xu; Xinwei Wang; Yanlin Wei; Li Li; Chao Li; Tianwang Li; Jianlin Huang; Yunfeng Pan; Ou Jin; Yuqiong Wu; Jing Wu; Zishi Guo; Peigen He; Shaoxian Hu; Husheng Wu; Hui Song; Feng Zhan; Shengyun Liu; Guanmin Gao; Zhangsuo Liu; Yinong Li; Changhong Xiao; Juan Li; Zhizhong Ye; Weizhen He; Dongzhou Liu; Lingxun Shen; Anbin Huang; Henglian Wu; Yi Tao; Xieping Pan; Buyun Yu; E Shyong Tai; Yi-Xin Zeng; Ee Chee Ren; Yan Shen; Jianjun Liu; Jieruo Gu
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

2.  Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis.

Authors:  Seung-Hyun Jung; Seon-Hee Yim; Hae-Jin Hu; Kyu Hoon Lee; Joo-Hyun Lee; Dong-Hyuk Sheen; Mi-Kyoung Lim; Soon-Young Kim; Sung-Won Park; So-Hee Kim; Kyudong Han; Tae-Hwan Kim; Seung-Cheol Shim; Yeun-Jun Chung
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

3.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

4.  Concordance of disease severity among family members with ankylosing spondylitis?

Authors:  Sinead Brophy; Sarah Hickey; Ajit Menon; Gordon Taylor; Linda Bradbury; Jasmin Hamersma; Andrei Calin
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

5.  Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation.

Authors:  Ofer Fainaru; Eilon Woolf; Joseph Lotem; Merav Yarmus; Ori Brenner; Dalia Goldenberg; Varda Negreanu; Yael Bernstein; Ditsa Levanon; Steffen Jung; Yoram Groner
Journal:  EMBO J       Date:  2004-02-05       Impact factor: 11.598

6.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

7.  Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.

Authors:  David M Evans; Chris C A Spencer; Jennifer J Pointon; Zhan Su; David Harvey; Grazyna Kochan; Udo Oppermann; Udo Opperman; Alexander Dilthey; Matti Pirinen; Millicent A Stone; Louise Appleton; Loukas Moutsianas; Loukas Moutsianis; Stephen Leslie; Tom Wordsworth; Tony J Kenna; Tugce Karaderi; Gethin P Thomas; Michael M Ward; Michael H Weisman; Claire Farrar; Linda A Bradbury; Patrick Danoy; Robert D Inman; Walter Maksymowych; Dafna Gladman; Proton Rahman; Ann Morgan; Helena Marzo-Ortega; Paul Bowness; Karl Gaffney; J S Hill Gaston; Malcolm Smith; Jacome Bruges-Armas; Ana-Rita Couto; Rosa Sorrentino; Fabiana Paladini; Manuel A Ferreira; Huji Xu; Yu Liu; Lei Jiang; Carlos Lopez-Larrea; Roberto Díaz-Peña; Antonio López-Vázquez; Tetyana Zayats; Gavin Band; Céline Bellenguez; Hannah Blackburn; Jenefer M Blackwell; Elvira Bramon; Suzannah J Bumpstead; Juan P Casas; Aiden Corvin; Nicholas Craddock; Panos Deloukas; Serge Dronov; Audrey Duncanson; Sarah Edkins; Colin Freeman; Matthew Gillman; Emma Gray; Rhian Gwilliam; Naomi Hammond; Sarah E Hunt; Janusz Jankowski; Alagurevathi Jayakumar; Cordelia Langford; Jennifer Liddle; Hugh S Markus; Christopher G Mathew; Owen T McCann; Mark I McCarthy; Colin N A Palmer; Leena Peltonen; Robert Plomin; Simon C Potter; Anna Rautanen; Radhi Ravindrarajah; Michelle Ricketts; Nilesh Samani; Stephen J Sawcer; Amy Strange; Richard C Trembath; Ananth C Viswanathan; Matthew Waller; Paul Weston; Pamela Whittaker; Sara Widaa; Nicholas W Wood; Gilean McVean; John D Reveille; B Paul Wordsworth; Matthew A Brown; Peter Donnelly
Journal:  Nat Genet       Date:  2011-07-10       Impact factor: 38.330

8.  Association Study of IL-12B Polymorphisms Susceptibility with Ankylosing Spondylitis in Mainland Han Population.

Authors:  Li Zhang; Dazhi Fan; Li Liu; Ting Yang; Ning Ding; Yanting Hu; Guoqi Cai; Li Wang; Lihong Xin; Qing Xia; Xiaona Li; Shengqian Xu; Jianhua Xu; Xiao Yang; Yanfeng Zou; Faming Pan
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

9.  Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.

Authors:  John D Reveille; Anne-Marie Sims; Patrick Danoy; David M Evans; Paul Leo; Jennifer J Pointon; Rui Jin; Xiaodong Zhou; Linda A Bradbury; Louise H Appleton; John C Davis; Laura Diekman; Tracey Doan; Alison Dowling; Ran Duan; Emma L Duncan; Claire Farrar; Johanna Hadler; David Harvey; Tugce Karaderi; Rebecca Mogg; Emma Pomeroy; Karena Pryce; Jacqueline Taylor; Laurie Savage; Panos Deloukas; Vasudev Kumanduri; Leena Peltonen; Sue M Ring; Pamela Whittaker; Evgeny Glazov; Gethin P Thomas; Walter P Maksymowych; Robert D Inman; Michael M Ward; Millicent A Stone; Michael H Weisman; B Paul Wordsworth; Matthew A Brown
Journal:  Nat Genet       Date:  2010-01-10       Impact factor: 38.330

10.  The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.

Authors:  Matteo Vecellio; Amity R Roberts; Carla J Cohen; Adrian Cortes; Julian C Knight; Paul Bowness; B Paul Wordsworth
Journal:  Ann Rheum Dis       Date:  2015-10-09       Impact factor: 19.103

View more
  6 in total

Review 1.  The Pathogenesis of Ankylosing Spondylitis: an Update.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2019-11-11       Impact factor: 4.592

Review 2.  The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science.

Authors:  Abdulla Watad; Charlie Bridgewood; Tobias Russell; Helena Marzo-Ortega; Richard Cuthbert; Dennis McGonagle
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

3.  RUNX3 Polymorphisms Affect the Risk of Ankylosing Spondylitis.

Authors:  Huawei Liu; Ligong Fu; Dawei He; Jiuzheng Deng; Jianjin Zhu; Kai Xu; Dong Hu; Jing Li; Yan Wang; Wenhao Hu; Songhua Xiao
Journal:  Med Sci Monit       Date:  2020-05-01

4.  ERAP1/ERAP2 and RUNX3 polymorphisms are not associated with ankylosing spondylitis susceptibility in Chinese Han.

Authors:  W Su; L Du; S Liu; J Deng; Q Cao; G Yuan; A Kijlstra; P Yang
Journal:  Clin Exp Immunol       Date:  2018-03-30       Impact factor: 4.330

5.  Protective effect of anthrax toxin receptor 2 polymorphism rs4333130 against the risk of ankylosing spondylitis.

Authors:  Haitao Xu; Yiming Qu
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

6.  Ankylosing spondylitis: etiology, pathogenesis, and treatments.

Authors:  Xu Cao; Xisheng Weng; Wei Zhu; Xuxia He; Kaiyuan Cheng; Linjie Zhang; Di Chen; Xiao Wang; Guixing Qiu
Journal:  Bone Res       Date:  2019-08-05       Impact factor: 13.567

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.